Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • Log out
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Basic Sciences

Effect of Flurbiprofen and 16,16-Dimethyl Prostaglandin E2 on Gastrointestinal Tumorigenesis Induced by N-Methyl-N′-nitro-N-nitrosoguanidine in Rats: Glandular Epithelium of Stomach and Duodenum

Thomas Lehnert, Eleanor E. Deschner, Rashida A. Karmali and Jerome J. DeCosse
Thomas Lehnert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eleanor E. Deschner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rashida A. Karmali
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jerome J. DeCosse
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published January 1990
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

The effect of an exogenous synthetic prostaglandin analogue, 16,16-dimethyl prostaglandin E2 (16,16-dm-PGE2), as well as the effect of endogenous prostaglandin synthesis inhibition by a cyclooxygenase inhibitor, flurbiprofen, on chemically induced gastric carcinogenesis has been investigated in rats. Carcinogenesis was induced by N-methyl-N′-nitro-N-nitrosoguanidine (MNNG; CAS:70-25-7). Animals were divided into six groups: Group I, treatment with MNNG alone; Group II, treatment with 16,16-dm-PGE2 plus MNNG; group III, treatment with flurbiprofen plus MNNG; Group IV, treatment with 16,16-dm-PGE2 alone; Group V, treatment with flurbiprofen alone; and Group VI, controls.

Treatment with high doses of MNNG resulted in rapid development of malignant tumors originating from the glandular epithelium of the stomach and duodenum in animals of all groups receiving the carcinogen. The first gastric adenocarcinoma infiltrating the muscularis proper was detected after 139 days in an animal treated with a combination of MNNG and flurbiprofen. The incidence of infiltrating adenocarcinoma and the incidence of all neoplastic lesions of the glandular stomach were both significantly higher in animals treated with a combination of MNNG and flurbiprofen compared with treatment by MNNG alone or in combination with 16,16-dm-PGE2 (P < 0.05 and P < 0.001). The difference in tumor incidence between the last two groups was not significant.

The first duodenal adenocarcinoma was detected on Day 114 in another animal of the group treated with MNNG plus flurbiprofen. When compared with the group treated with MNNG plus 16,16-dm-PGE2, significantly more animals developed duodenal adenocarcinoma when treated with MNNG plus flurbiprofen (P < 0.005) or with MNNG alone (P < 0.05).

Results of this study indicate that inhibition of endogenous prostaglandin synthesis favors development of adenocarcinoma in the glandular stomach of rats. Vice versa, the addition of an exogenous prostaglandin analogue inhibits the development of duodenal adenocarcinoma. This protective effect of prostaglandins may be due to an increase of the thickness of the mucus gel covering the glandular epithelium, thereby preventing access of carcinogen to the mucosa.

Footnotes

  • ↵1 This is the second paper in a series.

  • Received August 30, 1988.
  • Revision received August 21, 1989.
  • Accepted September 26, 1989.
  • ©1990 American Association for Cancer Research.
PreviousNext
Back to top
January 1990
Volume 50, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Effect of Flurbiprofen and 16,16-Dimethyl Prostaglandin E2 on Gastrointestinal Tumorigenesis Induced by N-Methyl-N′-nitro-N-nitrosoguanidine in Rats: Glandular Epithelium of Stomach and Duodenum
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Effect of Flurbiprofen and 16,16-Dimethyl Prostaglandin E2 on Gastrointestinal Tumorigenesis Induced by N-Methyl-N′-nitro-N-nitrosoguanidine in Rats: Glandular Epithelium of Stomach and Duodenum
Thomas Lehnert, Eleanor E. Deschner, Rashida A. Karmali and Jerome J. DeCosse
Cancer Res January 15 1990 (50) (2) 381-384;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Effect of Flurbiprofen and 16,16-Dimethyl Prostaglandin E2 on Gastrointestinal Tumorigenesis Induced by N-Methyl-N′-nitro-N-nitrosoguanidine in Rats: Glandular Epithelium of Stomach and Duodenum
Thomas Lehnert, Eleanor E. Deschner, Rashida A. Karmali and Jerome J. DeCosse
Cancer Res January 15 1990 (50) (2) 381-384;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Basic Sciences

  • Down-regulation by Interleukin 4 of Activation of Human Alveolar Macrophages to the Tumoricidal State
  • Allelic Loss on Chromosome 17p and p53 Mutations in Human Endometrial Carcinoma of the Uterus
  • Human T-Lymphocytes Targeted against an Established Human Ovarian Carcinoma with a Bispecific F(ab′)2 Antibody Prolong Host Survival in a Murine Xenograft Model
Show more Basic Sciences

Articles

  • Down-regulation by Interleukin 4 of Activation of Human Alveolar Macrophages to the Tumoricidal State
  • Allelic Loss on Chromosome 17p and p53 Mutations in Human Endometrial Carcinoma of the Uterus
  • Human T-Lymphocytes Targeted against an Established Human Ovarian Carcinoma with a Bispecific F(ab′)2 Antibody Prolong Host Survival in a Murine Xenograft Model
Show more Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement